Latest Market Launch News

Rhythm Biosciences has begun commercialising ColoSTAT®, its blood-based colorectal cancer diagnostic test, following an updated ISO15189, 2022 accreditation. The test offers a new option for symptomatic patients where stool-based screening is unsuitable.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

Island Pharmaceuticals has been granted a pivotal US patent extending protection for its antiviral drug Galidesivir as a Covid-19 treatment until 2042, reinforcing its strategic position in the antiviral market.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Finbar Group has completed settlement on a prime South Perth development site valued at approximately $187 million, advancing its substantial $1.2 billion project pipeline with a market launch planned for 2026.

Urbanise.com Limited has secured a landmark partnership with National Australia Bank to integrate banking services into its cloud-based strata management platform, marking a pivotal step in modernising an industry long reliant on legacy systems.

Light & Wonder, Inc. posted robust Q3 2025 results, driven by strong gaming operations and record iGaming revenue, while advancing its transition to a sole ASX listing.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

HITIQ Ltd has secured a landmark order for its PROTEQT™ mouthguards at the Winter Olympics and launched in the UK consumer market, while advancing global validation and raising over A$2 million in capital.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.